How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?

How do you see the future of access, affordability, and general utilization of PCSK9 inhibitors as a result of the price reductions and results from CV outcome trials?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic